075586725195
|
Set Home
|
Favorite
|
中文
Home
About Us
Our Company
Research team
Clinical trials
Clinical trials
Enrollment procedure
Treatment Options for Cancer
Case report
Case report
Research direction
Our Science
CART treatment
EIE treatment
Cancer vaccines
Gene therapy
Neoantigen Immunotherapy
GBM treatment
Publication
News
Newest Technology
Partners
Domestic partners
Foreign partners
FAQ
Neoantigen problem
31 questions
Contact Us
Contact us
Feedback
Home
About Us
Research team
Clinical trials
Case report
Research direction
News
Partners
FAQ
Contact Us
中文版
Newest Technology
Newest Technology
News
Newest Technology
Newest Technology
How many CAR-T infusions are needed for solid tumors？
The average overall survival period is less than 1 year, and most patients st ...
ASGCT 2020 Abstract：Safety Evaluation of Intracerebral Injection of LentiviralABCD1 for X-ALD Gene Therapy
...
ASGCT 2020 Abstract：Lentiviral Gene Therapy for Hemophilia B: Exploration of Endothelial Promoters in Mesenchymal Stem Cells
...
ASGCT 2020 Abstract：Lentiviral Gene Therapy of Hemophilia A: Expression and Functional Comparison of Universal and Tissue-specific Promoters
...
The COVID-19 vaccine development landscape
...
Previous
1
2
Next
ADD: 深圳市南山区粤兴二道6号虚拟大学园重点实验室平台二层 TEL: 075586725195 Email: gimi_trials@szgimi.org
Copyright © 2016 Shenzhen Genoimmune Medical Institute all rights reserved.
Newest Technology 
